UCB SA (LON:0NZT)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 41.81B +63.1% |
| Revenue (ttm) | 6.75B +25.8% |
| Net Income | 1.36B +46.3% |
| EPS | 7.01 +46.5% |
| Shares Out | n/a |
| PE Ratio | 30.76 |
| Forward PE | 23.49 |
| Dividend | 0.88 (0.35%) |
| Ex-Dividend Date | May 4, 2026 |
| Volume | 221,370 |
| Open | 249.05 |
| Previous Close | 251.95 |
| Day's Range | 246.90 - 257.20 |
| 52-Week Range | 154.00 - 289.50 |
| Beta | 0.17 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for... [Read more]
Financial Performance
In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.
Financial numbers in EUR Financial StatementsNews
UCB to Buy Candid Therapeutics for Up to $2.2 Billion
The deal seeks to bolster the company's pipeline of experimental treatments for autoimmune and inflammatory diseases.
Belgian pharma group UCB to buy Candid Therapeutics for up to $2.2 billion
Belgian biopharmaceuticals company UCB has agreed to buy privately-held Candid Therapeutics in a deal worth up to $2.2 billion, the companies said on Sunday.
UCB SA Slides: Acquisition presentation
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on May 3, 2026.
Belgium's UCB in autoimmune drug deal with Antengene
Belgian drugmaker UCB has entered into an agreement to licence Antengene's experimental autoimmune disease therapy ATG-201 and associated technology, paying $60 million up front and over $1.1 billio...
UCB SA Earnings Call Transcript: H2 2025
Net sales surged 35% year-over-year, led by Bimzelx and four other growth drivers, with strong pipeline progress and a robust financial position. 2026 guidance anticipates continued high single to low double-digit revenue growth and margin expansion, supported by strategic investments and portfolio differentiation.
UCB SA Annual report: H2 2025
UCB SA has published its H2 2025 annual report on February 26, 2026.
UCB SA Slides: H2 2025
UCB SA has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 26, 2026.
UCB SA Transcript: 44th Annual J.P. Morgan Healthcare Conference
A decade of growth is anticipated, driven by five key products in immunology and neurology, robust R&D investment, and a strong pipeline. Market access for BIMZELX is expanding, with new indications and head-to-head studies expected to fuel further growth.
UCB SA Slides: 44th Annual J.P. Morgan Healthcare Conference
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on January 14, 2026.
U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
Approved indication: KYGEVVI® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with...
UCB SA Earnings Call Transcript: H1 2025
First-half 2025 saw 26% net sales growth, led by BIMZELX and strong pipeline progress. Upgraded full-year guidance reflects confidence in continued momentum, despite pricing and currency headwinds. BIMZELX's global expansion and new indications underpin robust financial and operational performance.
UCB SA Earnings release: H1 2025
UCB SA released its H1 2025 earnings on July 31, 2025, summarizing the period's financial results.
UCB SA Slides: H1 2025
UCB SA has posted slides in relation to its H1 2025 quarterly earnings report, which was published on July 31, 2025.